{"product_id":"recombinant-human-tnf-alpha-tnfa-protein-aa-77-233-his-tagactive-pksh033164","title":"Recombinant Human TNF-alpha\/TNFA Protein (aa 77-233, His Tag)(Active) - PKSH033164","description":"Recombinant Human TNF-alpha\/TNFA Protein (aa 77-233, His Tag)(Active)\n\nSize: 100μg\n\nCatalogue Number: PKSH033164-100\n\nCitations, Manuals and MSDS Available upon request.\n\nAbbreviation: TNF-alpha; TNFA\n\nTarget Symptom: Tumor Necrosis Factor; Cachectin; TNF-Alpha; Tumor Necrosis Factor Ligand Superfamily Member 2; TNF-a; TNF; TNFA; TNFSF2\n\nResearch Area: Signal Transduction; Cardiovascular; Cancer; immunology; metabolism; \n\nTarget Species: Human\n\nExpression Host: E.coli\n\nApplication: Cell culture\n\nFusion Tag: C-6His\n\nUNIProt ID: P01375\n\nAccession: P01375\n\nBackground: Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages; monocytes; neutrophils; T-cells; and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons; IL2; and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever; dose-limiting hypotension; hepatotoxicity; intravascular thrombosis; and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7; exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α; which binds to both murine TNF receptors. Based on these results; many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8; Lys9; Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.\n\nActivity: Measure by its ability to induce cytotoxicity in L929 cells in the presence of actinomycin D. The ED50 for this effectis \u0026lt; 0.1 ng\/mL. The specific activity of recombinant human TNF alpha is approximately 1x 10\u003csup\u003e7\u003c\/sup\u003e IU\/mg.\n\nSequence: Val77-Leu233\n\nPurity: \u0026gt; 95 % as determined by reducing SDS-PAGE.\n\nFormulation: Lyophilized from a 0.2 μm filtered solution of 20mM PB; 150mM NaCl; pH7.4.\nNormally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.\nPlease refer to the specific buffer information in the printed manual.\n\nReconstitution: Please refer to the printed manual for detailed information.\n\nEndotoxin: \u0026lt; 1.0 EU per μg of the protein as determined by the LAL method.\n\nCalculated MW: 18.5 kDa\n\nObserved MW: 16 kDa\n\nStorage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at \u0026lt; -20℃ for 3 months.\n\nShipping: This product is provided as lyophilized powder which is shipped with ice packs.\n\nResearch Use Only","brand":"Elabscience","offers":[{"title":"Default Title","offer_id":43107264987315,"sku":"PKSH033164-100","price":348.6,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0305\/9482\/6376\/products\/logo_new_fccbbf8a-009b-4d71-92e3-42e98245175b.png?v=1709382163","url":"https:\/\/afsbio.com\/products\/recombinant-human-tnf-alpha-tnfa-protein-aa-77-233-his-tagactive-pksh033164","provider":"AFSBio Inc.","version":"1.0","type":"link"}